Moderna Wins First mRNA Flu Approval; CVS Expands Lilly Tie

Moderna ($MRNA) secured FDA approval for mFLUSIVA, the first messenger RNA-based influenza vaccine, cleared for adults aged 50 and over. The approval marks $MRNA's fourth FDA-cleared product and represents a significant platform expansion beyond COVID-19 vaccines. Despite the regulatory milestone, $MRNA stock declined, with shares down 31.23% over one month while posting an 82.29% year-to-date gain and 110.61% one-year total shareholder return. Novavax raised its full-year 2026 adjusted total revenue outlook to $235–$275 million from $230–$270 million, driven by progress in its Matrix-M adjuvant platform and new partnership deals across infectious disease and oncology. The global influenza vaccine market was valued at $8.96 billion in 2024 and is projected to reach $13.32 billion by 2030, expanding at a compound annual growth rate of approximately 7% between 2025 and 2030, according to ResearchAndMarkets.com. Market growth is being supported by rising public health awareness, an expanding geriatric population, and government immunization programs.

CVS Health ($CVS) reported second-quarter results showing revenue of $106.10 billion and net income of $2,979 million, with materially higher earnings per share versus a year earlier. On the same day, $CVS raised its 2026 earnings guidance and expanded its GLP-1 weight management offering through a new collaboration with Eli Lilly ($LLY), underscoring how integrated pharmacy, insurance, and care-delivery assets can be combined. Despite the earnings beat and raised guidance, $CVS shares fell 8.6% in early August. The expanded $LLY partnership positions $CVS to broaden access to GLP-1 therapies through its pharmacy and insurance network.

CytomX Therapeutics ($CTMX) reported second-quarter results with continued focus on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. $CTMX expects a Phase 1 monotherapy update in advanced colorectal cancer by the end of 2026, with a registrational study planned for initiation in the first half of 2027. Phase 1/2 chemotherapy combination studies focused in second-line metastatic colorectal cancer are initiating in Q4 2026, and Phase 1 monotherapy expansion cohorts are initiating in Q3 2026 in gastric, gastroesophageal junction, and EpCAM-selected pancreatic ductal adenocarcinoma. A market analysis covering endometrial cancer highlighted opportunities centered on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, and precision therapies for uterine sarcomas, featuring players including Merck ($MRK), Eisai, Karyopharm Therapeutics, Context Therapeutics, and Seagen.

The global gRNA market was valued at approximately $518 million in 2024 and is expected to reach $616 million in 2025, with projections to reach $2,950 million by 2034 at a compound annual growth rate of 19% between 2025 and 2034, according to Custom Market Insights. Key market players listed include Thermo Fisher Scientific ($TMO) and Agilent Technologies, reflecting the growing demand for CRISPR-related tools and gene-editing technologies. Baillie Gifford's Q2 2026 13F filing showed its portfolio grew to $110 billion, with holdings including DexCom ($DXCM) among its positions.

Positive readouts in cancer and cardiac drug trials could drive further momentum for biotech and pharma stocks, with upcoming data expected from Merck ($MRK), Moderna ($MRNA), and Summit Therapeutics. CytomX plans to initiate Phase 1 monotherapy expansion cohorts in Q3 2026 and chemotherapy combination studies in Q4 2026, with a registrational study planned for first half 2027. The global nutritional market was valued at approximately $660.6 billion in 2024 and is expected to reach $731.9 billion in 2025, with projections to reach $1,819.6 billion by 2034 at a compound annual growth rate of 10.6%, with key players including Abbott Laboratories ($ABT) and Glanbia.